Eyeing emergency use of COVID-19 drug, Humanigen partners with Lonza to make it
pharmaphorum
SEPTEMBER 15, 2020
Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to make sure it can meet demand. Lilly also has studies on the go for LY3127804, an investigational antibody targeting angiopoietin 2 (Ang2).
Let's personalize your content